JP2013532130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532130A5 JP2013532130A5 JP2013510364A JP2013510364A JP2013532130A5 JP 2013532130 A5 JP2013532130 A5 JP 2013532130A5 JP 2013510364 A JP2013510364 A JP 2013510364A JP 2013510364 A JP2013510364 A JP 2013510364A JP 2013532130 A5 JP2013532130 A5 JP 2013532130A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- compound
- pharmaceutically acceptable
- acceptable salt
- structural formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (5)
からなる群より選択される構造式で表される化合物、またはその薬学的に許容され得る塩。
A compound represented by a structural formula selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
で表される請求項1に記載の化合物、またはその薬学的に許容され得る塩。 Structural formula
The compound of Claim 1 represented by these, or its pharmaceutically acceptable salt.
で表される請求項1に記載の化合物、またはその薬学的に許容され得る塩。 Structural formula
The compound of Claim 1 represented by these, or its pharmaceutically acceptable salt.
で表される請求項2に記載の化合物、またはその薬学的に許容され得る塩。 Structural formula
The compound of Claim 2 represented by these, or its pharmaceutically acceptable salt.
で表される請求項3に記載の化合物、またはその薬学的に許容され得る塩。
Structural formula
The compound of Claim 3 represented by these, or its pharmaceutically acceptable salt.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33499110P | 2010-05-14 | 2010-05-14 | |
US61/334,991 | 2010-05-14 | ||
US37074510P | 2010-08-04 | 2010-08-04 | |
US61/370,745 | 2010-08-04 | ||
US37586310P | 2010-08-22 | 2010-08-22 | |
US61/375,863 | 2010-08-22 | ||
PCT/US2011/036701 WO2011143669A2 (en) | 2010-05-14 | 2011-05-16 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015049960A Division JP5937247B2 (en) | 2010-05-14 | 2015-03-12 | Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013532130A JP2013532130A (en) | 2013-08-15 |
JP2013532130A5 true JP2013532130A5 (en) | 2014-11-06 |
JP5715241B2 JP5715241B2 (en) | 2015-05-07 |
Family
ID=49052897
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013510364A Active JP5715241B2 (en) | 2010-05-14 | 2011-05-16 | Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders |
JP2015049960A Active JP5937247B2 (en) | 2010-05-14 | 2015-03-12 | Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015049960A Active JP5937247B2 (en) | 2010-05-14 | 2015-03-12 | Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP5715241B2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5913292B2 (en) * | 2010-05-14 | 2016-04-27 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Compositions and methods for modulating metabolism |
PT2571503E (en) | 2010-05-14 | 2015-04-29 | Dana Farber Cancer Inst Inc | Compositions and their use in treating neoplasia, inflammatory disease and other disorders |
CN105050605A (en) * | 2012-06-25 | 2015-11-11 | 翁科埃蒂克斯股份公司 | Method of treating lymphoma using thienotriazolodiazepine compounds |
EP3030242A1 (en) * | 2013-08-06 | 2016-06-15 | Oncoethix GmbH | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
WO2015070020A2 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
MX2016011160A (en) | 2014-02-28 | 2017-04-27 | Tensha Therapeutics Inc | Treatment of conditions associated with hyperinsulinaemia. |
CN107787227A (en) * | 2015-06-26 | 2018-03-09 | 腾沙治疗公司 | The treatment of NUT center line cancers |
JP2018526421A (en) * | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Cyanothienotriazolodiazepines and their use |
SG10202007099TA (en) * | 2015-09-11 | 2020-08-28 | Dana Farber Cancer Inst Inc | Acetamide thienotriazoldiazepines and uses thereof |
CA2999523A1 (en) * | 2015-10-02 | 2017-04-06 | Dana-Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
AU2017219627B2 (en) * | 2016-02-15 | 2021-08-05 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors |
MX2019006956A (en) * | 2016-12-16 | 2019-08-01 | Hoffmann La Roche | Process for the manufacture of diazepine derivatives. |
CN109503618A (en) * | 2017-09-14 | 2019-03-22 | 成都海创药业有限公司 | A kind of BRD4 inhibitor |
WO2019238557A1 (en) * | 2018-06-13 | 2019-12-19 | Dybly Ag | Preparation of condensed triazepine derivatives and their use as bet inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1227555A (en) * | 1996-06-12 | 1999-09-01 | 日本烟草产业株式会社 | Cytokine production inhibitors triazepine compounds, and intermediates thereof |
US7589167B2 (en) * | 2000-02-22 | 2009-09-15 | J. David Gladstone Institutes | ZA loops of bromodomains |
AU2004215359A1 (en) * | 2003-02-27 | 2004-09-10 | Abbott Laboratories | Heterocyclic kinase inhibitors |
CA2710740C (en) * | 2007-12-28 | 2016-07-19 | Shinji Miyoshi | Thienotriazolodiazepine compound as antitumor agent |
KR20120097508A (en) * | 2009-11-05 | 2012-09-04 | 글락소스미스클라인 엘엘씨 | Benzodiazepine bromodomain inhibitor |
-
2011
- 2011-05-16 JP JP2013510364A patent/JP5715241B2/en active Active
-
2015
- 2015-03-12 JP JP2015049960A patent/JP5937247B2/en active Active